General Information of Drug (ID: DMWSL5G)

Drug Name
PMID28447479-Compound-20 Drug Info
Cross-matching ID
PubChem CID
78425825
TTD Drug ID
DMWSL5G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cudetaxestat DMYLDN9 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [2]
PMID28447479-Compound-24 DMDOVIZ N. A. N. A. Patented [1]
Tetra-hydro-carboline derivative 2 DMXTL7V N. A. N. A. Patented [1]
PMID28447479-Compound-14 DMA91X2 N. A. N. A. Patented [1]
Pyrimidinone derivative 5 DMLFY57 N. A. N. A. Patented [1]
Heteroaromatic ring derivative 3 DMKJL5T N. A. N. A. Patented [1]
Pyrazolo[3,4-c]pyridine derivative 1 DMQHCDZ N. A. N. A. Patented [1]
Pyrazole derivative 87 DMGZUAY N. A. N. A. Patented [1]
Pyridine and pyrimidine derivative 1 DMGEYJW Fibrosis GA14-GC01 Patented [1]
Imidazopyrimidinone derivative 1 DMWN17V N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Extracellular lysophospholipase D (E-NPP2) TTSCIM2 ENPP2_HUMAN Inhibitor [1]

References

1 Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829.
2 An updated patent review of autotaxin inhibitors (2017-present). Expert Opin Ther Pat. 2021 May;31(5):421-434.